The Rockefeller University

Urecap Corporation

Attallah Kappas

George S Drummond

Darryl Rideout

Daniel W Rosenberg

Robert B Polak

Richard A Galbraith

Lennart Emtestam

A method of treating a mammal for the presence or the activity of H. pylori in the gastrointestinal tract is disclosed. The method encompasses orally administering to said mammal a sufficient amount of a scavenging, reacting or inactivating compound to remove bicarbonate ions, ammonium ions or urea which are present in combination with the microorganisms which colonize and infect the gastric mucosa. Such microorganisms have been implicated in gastritis, gastric ulcer disease and as a risk factor in gastric carcinoma. Also, the invention encompasses a method, utilizing similar compounds, for the treatment or prevention of dermatitis such as diaper rash wherein these compounds are preapplied to the skin or used to treat the diaper prior to use. Also included are compositions which are used for the methods described above.

Method and compositions for the treatment of H. pylori and dermatitis

Disclosed is a pharmaceutical composition for oral administration to control heme oxygenase comprising mettaloprotoporhyrins and mettalomesoporphyrins.

Orally administered porphyrins to control intestinal iron absorption

The administration of tin protoporphyrin, tin mesoporphyrin or tin diiododeuteroporphyrin to mammals, notably humans, increases the rate at which heme is excreted by mammals, and is useful for treatment of body tissue injury associated with hemorrhage in the body.

Control of heme and iron concentrations in body tissues

Method of decreasing the production of thyroid hormones in animals by parenteral administration of defined quantities of cobalt protoporphyrin or cobalt mesoporphyrin.

Method of controlling T.sub.3 and T.sub.4 levels in vivo with cobalt

Cobalt protoporphyrin and cobalt mesoporphyrin are administered to animals to achieve weight loss and improve protein to fat ratio.

Methods for suppressing the endocrine system

Method for limiting the production of estrogenic steroids by parenteral administration of selected amounts of cobalt protoporphyrin or cobalt mesoporphyrin.

Method for suppressing the endocrine system

Method of reducing the production of gonadal estrogenic steroidal hormones in animals by parenteral administration of defined quantities of cobalt protoporphyrin or cobalt mesoporphyrin.

Method of controlling androstene levels in vivo with cobalt porphyrins

A method for reducing the copper burden in mammals without zincuresis utilizing cobalt salts or chelates.

Use of cobalt to enhance urinary copper excretion

Pharmaceutical copositions comprising liposomal metalloporphyrins are provided for parenteral administration to mammals, including humans. These liposomal metalloporphyrins selectively target the spleen and markedly inhibit the heme oxygenase activity therein. A method is also provided for intravenous administration of these compositions to mammals to selectively target the spleen.

Use of liposomes as carriers for metalloporphyrins

Cobalt protoporphyrin and cobalt mesoporphyrin are administered to animals to achieve weight loss and improved protein to fat ratio without decrease in hormone concentration.

Method of weight control by low level administration of cobalt

This invention relates to the parenteral administration of cobalt protoporphyrin and cobalt mesoporphyrin to suppress the endocrine system of animals to achieve physiological effects such as suppression of the production of gonadal or thyroid hormones, control of weight gain and improved protein to fat ratio.

Use of tin protoporphyrin and tin mesoporphyrin together with ultraviolet light in the treatment of psoriasis.

Tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis

Use of the novel compound tin diiododeuteroporphyrin and compositions containing it to inhibit heme mebabolism in mammals, to control the rate of tryptophan metabolism in mammals, and to increase the rate at which heme and iron are excreted by mammals.

Therapeutic use of tin diiododeuteroporphyrin

Use of the novel compound tin diiododeuteroporphyrin and compositions containing it to inhibit heme metabolism in mammals, to control the rate of tryptophan metabolism in mammals, and to increase the rate at which heme and iron are excreted by mammals.

Use of the novel compound tin mesoporphyrin and compositions containing it to inhibit heme metabolism in mammals, to control the rate of tryptophan metabolism in mammals, and to increase the rate at which heme is excreted by mammals.

Growing community of inventors

New York, NY, United States of America

Attallah Kappas